Table 2.
Available clinical data on BRAF V600E mutated GBM and eGBM treated with BRAF inhibitors alone or in combination.
| Author | Drug | Study type | Tumor type | N. patients | Best Response |
|---|---|---|---|---|---|
| Robinson et al. (57) | vemurafenib | case report | V600E GBM | 1 | CR |
| Burger et al. (53) | dabrafenib | case report | V600E GBM | 1 | CR |
| Ceccon et al. (54) | dabrafenib | case report | V600E eGBM | 1 | SD |
| Qin C et al. (58) | dabrafenib | case report | V600E GBM | 1 | PR |
| Beba et al. (52) | vemurafenib | case report | V600E GBM | 1 | SD |
| Schreck et al. (59) | dabrafenib + trametinib | case report | V600E eGBM | 1 | SD |
| Kushnirsky et al. (60) | dabrafenib + trametinib | case report | V600E GBM | 1 | CR |
| Kanemaru et al. (61) | dabrafenib + trametinib | case report | V600E eGBM | 1 | PR |
| Johanns et al. (55) | dabrafenib + trametinib | case report | V600E eGBM | 1 | PR |
| Kaley et al. (56) | vemurafenib | basket trial | V600E GBM | 11 | ORR 11% |
| Wen et al. (62) | dabrafenib + trametinib | basket trial | V600E GBM | 31 | ORR 33% |